Special considerations for the diagnosis and treatment of invasive pulmonary aspergillosis

ABSTRACT

Introduction: The diagnosis and treatment of invasive pulmonary aspergillosis (IPA) are ongoing challenges in clinical practice. While important advances have recently been made, including enhanced diagnostic modalities as well as novel therapeutic and prophylactic options, more effective options are urgently needed as the population of immunocompromised patients continues to expand.

Areas covered: In this paper, we review novel approaches to diagnosis of IPA, including multiplex PCR, Matrix Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry and provide a detailed review of the extended-spectrum triazole isavuconazole, which was approved in 2015 to treat IPA.

Expert commentary: We explore burgeoning approaches to diagnosis, including the lateral flow assay, volatile organic compounds, and artificial olfactory technology, as well as novel antifungal agents to treat IPA such as SCY-078 and F901318.

KEYWORDS:

• Isavuconazole
• eNose
• MALDI-TOF
• SCY-078
• combination therapy
• lateral
• flow assay

Declaration of interest

M. McCarthy has served as a paid consultant to Allergan. T.J. Walsh has served as a paid consultant to Allergan, Actavis, Theravance, iCo, Drais, SigmaTau and Methylgene. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Additional information

Funding

This paper was not funded.